四项激肽释放酶组合联合前列腺体积对高级别前列腺癌判别力的个体患者数据荟萃分析
该个体患者数据荟萃分析纳入9131例总PSA≤25 ng/ml且具备前列腺体积的患者,评估在四项激肽释放酶组合(4Kscore)模型中加入前列腺体积是否改善对ISUP分级分组2级及以上(GG2+)疾病的判别力。结果显示组合模型AUC为0.817(95%CI 0.802, 0.831),加入体积后AUC差异仅0.002(95%CI -0.003, 0.006),不支持将前列腺体积纳入四项激肽释放酶组合。
要点
- 四项激肽释放酶组合对GG2+前列腺癌的AUC为0.817(95%CI 0.802, 0.831)。
- 加入前列腺体积后判别力无改善,AUC差异0.002(95%CI -0.003, 0.006)。
- 仅一个学术癌症中心队列显示AUC增加0.044(95%CI 0.025, 0.064),存在异质性。
核心结论
- 四项激肽释放酶组合可无创评估高级别前列腺癌风险。
- 结果不支持将前列腺体积纳入四项激肽释放酶组合以改善判别力。
- 前列腺体积的预测价值可能依赖提供者,需进一步研究。
研究设计与样本
- 个体患者数据荟萃分析,纳入5个历史队列(六点穿刺活检、2005年前ISUP分级)和4个当代队列(10针以上穿刺、2005年ISUP分级)。
- 共9131例患者,具备前列腺体积且总PSA≤25 ng/ml。
- 使用既往发表的激肽释放酶组合模型预测GG2+风险,在各队列中加入体积并荟萃分析判别力变化。
主要发现
- 在7/9个队列中,控制激肽释放酶组合后,前列腺体积增大与GG2+疾病风险降低相关。
- 激肽释放酶组合判别力AUC为0.817(95%CI 0.802, 0.831),加入体积后AUC差异为0.002(95%CI -0.003, 0.006)。
- 异质性(P <.0001)由1个学术癌症中心队列的AUC增加驱动(0.044,95%CI 0.025, 0.064),排除该队列后无异质性证据(P = .15)。
关键数值与推荐
- 四项激肽释放酶组合对GG2+疾病的AUC为0.817(95%CI 0.802, 0.831)。
- 加入前列腺体积后AUC差异为0.002(95%CI -0.003, 0.006)。
- 学术癌症中心队列AUC增加0.044(95%CI 0.025, 0.064)。
临床怎么用
- 四项激肽释放酶组合可仅凭抽血评估高级别前列腺癌风险,无需影像测量前列腺体积。
- 临床不应常规将前列腺体积加入四项激肽释放酶组合以提升判别力。
局限性
- 前列腺体积的预测价值可能依赖提供者,需进一步研究。
- 异质性来源部分未明,仅一个学术癌症中心队列显示获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether adding prostate volume to the kallikrein panel improves discrimination for ISUP Grade Group 2 or higher (GG2+) disease, as some men may have volume measurements available at the time of blood draw. While prostate volume predicts biopsy outcome, it requires an imaging procedure for measurement. The four kallikrein panel - commercially available as the 4Kscore - predicts risk of GG2+ disease and requires only a blood draw. MATERIALS AND METHODS: A total of 9131 patients with available prostate volume and total PSA ≤25 ng/ml from 5 historical (sextant biopsy, pre-ISUP 2005 grading) and 4 contemporary cohorts (10+ cores, ISUP 2005 grading). Previously published kallikrein panel models were used to predict risk of GG2+. Volume was added to the model in each cohort and change in discrimination was meta-analyzed. RESULTS: Increased prostate volume was associated with decreased risk of GG2+ disease after controlling for the kallikrein panel in 7/9 cohorts. However, kallikrein panel discrimination (0.817, 95% CI 0.802, 0.831) was not improved after including volume (AUC difference 0.002, 95% CI -0.003, 0.006). Heterogeneity (P <.0001) was driven by an AUC increase in 1 cohort of academic cancer centers (0.044, 95% CI 0.025, 0.064), with no evidence of heterogeneity after excluding this cohort (P = .15). CONCLUSION: The kallikrein panel provides a non-invasive approach to assess the risk of high-grade prostate cancer. Our results do not justify the inclusion of prostate volume in the four kallikrein panel. There is some evidence that the predictive value of prostate volume is provider dependent: further research is needed to address this question.
引用
- Vertosick EA, Zappala S, Punnen S, et al. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology. 2021. PMID: 34450175. doi:10.1016/j.urology.2021.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。